ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, Dr. Tian Wenzhi, the company's founder and chairman, will participate The 26th BIO CEO & Investor Conference which will be held in New York, USA from February 26th to 27th, to deliver a speech at 1:45pm on February 26, 2024 EST to fully demonstrate ImmuneOnco's innovative product pipeline and clinical research and development progress.

The BIO CEO & Investor Conference is one of the premier investor conferences for established and emerging public companies as well as top private biotech companies. As a neutral forum, the BIO CEO and Investor Conference provides institutional investors, industry analysts and biotechnology company executives with an opportunity to build the future investment landscape of the biotechnology industry. For more conference details, please check the BIO official website: https://bcic.bio.org/